2012-09-20T11:19:12-05:00 2011-12-31 522041603 SQUIRE LEMKIN COMPANY LLP 111 ROCKVILLE PIKE SUITE 475 ROCKVILLE MD 20850 990 2011-01-01 202897110 BLADDER CANCER ADVOCACY NETWORK INC BLAD 3012159099 4915 ST ELMO AVENUE NO 202 BETHESDA MD 20814 DIANE QUALE 3012159099 2012-09-12 1 CLINT LEHMAN P00840525 3014246800 2011 2016-02-24 21:20:13Z DIANE QUALE 4915 ST ELMO AVENUE NO 202 BETHESDA MD 20814 772018 0 X WWW.BCAN.ORG X 2005 MD TO RAISE AWARENESS AND ADVANCE RESEARCH OF BLADDER CANCER; PROVIDE EDUCATION AND SUPPORT TO THE BLADDER CANCER COMMUNITY. 9 8 8 0 0 0 391754 737781 55579 34172 399 65 80 0 447812 772018 25000 25000 0 0 174261 313528 0 0 68243 299460 426841 498721 765369 -50909 6649 307882 317334 96797 99600 211085 217734 X TO INCREASE PUBLIC AWARENESS ABOUT BLADDER CANCER; TO ADVOCATE BLADDER CANCER RESEARCH; AND TO PROVIDE EDUCATIONAL AND SUPPORT SERVICES FOR THE BLADDER CANCER COMMUNITY. 0 0 212562 0 OUTREACH AND ADVOCACY- BCAN PROVIDES INFORMATION, RESOURCES AND SUPPORT TO BLADDER CANCER SURVIVORS, THEIR FAMILIES AND CAREGIVERS, AND THE MEDICAL COMMUNITY THROUGH OUR INTERACTIVE WEBSITE WHICH OFFERS A USER-FRIENDLY RESOURCE FOR PATIENTS, CLINICIANS AND CAREGIVERS AS WELL AS INSPIRATIONAL STORIES FROM SURVIVORS AND AN ONLINE COMMUNITY WHERE PATIENTS AND CAREGIVERS CAN FIND SUPPORT AND INFORMATION FROM OTHERS WHO ARE LIVING WITH THE DISEASE. THE STAFF RESPONDS TO REQUESTS FOR INFORMATION WHICH COMES THROUGH OUR OFFICE. BCAN STAFF, ALONG WITH LOCAL VOLUNTEERS, FACILITATED THE DEVELOPMENT OF SUPPORT GROUPS IN ROCHESTER, NY, INDIANAPOLIS, IN, AND MILWAUKEE, WI. MEMBERS OF OUR GROWING VOLUNTEER NETWORK HAVE PERSONALLY SPOKEN WITH OVER 750 UROLOGY PRACTICES AND CANCER CENTERS IN OVER 30 STATES TO DISTRIBUTE BCAN'S EDUCATIONAL INFORMATION TO OVER 3,000 PHYSICIANS. BCAN HAS DISTRIBUTED OVER 20,000 OF OUR COMPREHENSIVE PATIENT HANDBOOK, "BLADDER CANCER BASICS FOR THE NEWLY DIAGNOSED," TO SURVIVORS, CAREGIVERS, UROLOGY PRACTICES AND CANCER CENTERS ACROSS THE UNITED STATES. BCAN IS A MEMBER OF THE CANCER LEADERSHIP COUNCIL AND ONE VOICE AGAINST CANCER. BCAN PARTICIPATED IN THE ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL ONCOLOGY AND THE AMERICAN UROLOGICAL ASSOCIATION, AND NOMINATED VOLUNTEERS TO SERVE AS PATIENT ADVOCATES AT THE SOUTHWEST ONCOLOGY GROUP AND THE DEPARTMENT OF DEFENSE'S CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS. 88630 34172 EDUCATION AND INFORMATION - BCAN HELD THREE REGIONAL PATIENT FORUMS AT DIFFERENT VENUES IN THE COUNTRY WHICH GAVE PATIENTS AND THEIR CAREGIVERS AN OPPORTUNITY TO LEARN MORE ABOUT THEIR DISEASE FROM RECOGNIZED MEDICAL EXPERTS. CLOSE TO 300 SURVIVORS AND CAREGIVERS HEARD PRESENTATIONS ON BLADDER CANCER FROM EXPERTS IN THE FIELD AT PATIENT FORUMS IN LOS ANGELES, DENVER AND HOUSTON. THESE PRESENTATIONS ARE NOW AVAILABLE ON THE BCAN WEBSITE. BCAN CONTINUES TO DEVELOP ADDITIONAL EDUCATIONAL RESOURCES FOR SURVIVORS, CAREGIVERS, AND THE MEDICAL COMMUNITY. 263667 25000 0 RESEARCH - BCAN WORKS TO ADVANCE BLADDER CANCER RESEARCH. BCAN HOSTS THE ONLY ANNUAL SCIENTIFIC CONFERENCE IN NORTH AMERICA SOLELY FOCUSED ON BLADDER CANCER RESEARCH, THE BLADDER CANCER THINK TANK. THIS YEAR, BCAN RAISED $25,000 FOR OUR ANNUAL BCAN AWARD FOR BLADDER CANCER RESEARCH. THE GRANT PERIOD RUNS FROM JULY THROUGH JUNE OF THE FOLLOWING YEAR. FOR THE 2010 GRANT PERIOD, JULY 2010 - JUNE 2011, THE AWARD SUPPORTED DR. ELIZABETH GUANCIAL OF THE DANA-FARBER CANCER INSTITUTE. FOR THE 2011 GRANT PERIOD, JULY 2011 - JUNE 2012, THE AWARD SUPPORTED DR. GIL REDELMAN-SIDI OF THE MEMORIAL SLOAN-KETTERING CANCER CENTER. 564859 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 10 0 1 8 1 0 0 0 0 0 1 1 0 0 0 0 X 9 8 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD IL CA CT FL MA MI MO NJ NY OH PA RI VA WA GA X X THE ORGANIZATION 3012159099 4915 ST ELMO AVENUE NO 202 BETHESDA MD 20814 DIANE ZIPURSKY QUALE 25.00 X X 41879 0 0 JANICE ASHLEY 2.00 X 0 0 0 SETH LERNER 2.00 X 0 0 0 DAVID PULVER 2.00 X 0 0 0 MACE ROSENSTEIN 2.00 X X 0 0 0 RICHARD SCOLIO 2.00 X 0 0 0 JARED SHER 2.00 X X 0 0 0 ROBERT LEVIN 2.00 X 0 0 0 WILLIAM SHIPLEY 2.00 X 0 0 0 LAWRENCE RZEPKA 40.00 X 120517 0 0 162396 0 0 1 0 0 0 0 737781 737781 CONFERENCE INCOME 900099 27009 27009 OTHER INCOME 900099 7163 7163 34172 65 65 772018 34172 0 65 25000 25000 179129 114977 38326 25826 114406 98265 15731 410 8681 6544 858 1279 11312 7153 3450 709 235 200 10 25 21986 21986 2869 1725 1069 75 40452 39883 323 246 69398 19327 26124 23947 34832 26124 4354 4354 60271 50642 3022 6607 161844 159053 1396 1395 4239 4239 1076 1076 DUES AND MEMBERSHIP 10950 4066 6474 410 LICENSES & PERMITS 9676 5813 928 2935 BOARD EXPENSES 6817 5211 1606 REPAIRS AND MAINTENANCE 1591 550 1041 605 326 254 25 765369 564859 132267 68243 291835 272365 5015 20129 2035 1966 1957 6436 20092 11349 7040 8743 0 7695 307882 317334 96797 42100 37500 20000 96797 99600 X 211085 217734 211085 217734 307882 317334 6649 0 X 0 1 1 X 0 X 215883 337981 345406 387929 737781 2024980 215883 337981 345406 387929 737781 2024980 488097 1536883 6842 5032 2401 399 65 14739 2039719 153539 0.75350 0.71550 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 20092 11349 8743 8743 772018 765369 6649 6649 772018 0 772018 0 772018 765369 0 765369 0 765369 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X: BCAN IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. HOWEVER, INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO BCAN'S TAX-EXEMPT PURPOSE IS SUBJECT TO TAXATION AS UNRELATED BUSINESS INCOME. FOR THE YEARS ENDED DECEMBER 31, 2011 AND 2010, THERE WAS NO UNRELATED BUSINESS INCOME. FOR THE YEARS ENDED DECEMBER 31, 2011 AND 2010, NO UNRECOGNIZED TAX PROVISION OR BENEFIT EXISTS. 1 RESEARCH 1 25000 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: FOR A 12 MONTH GRANT PERIOD: THE RECIPIENT IS REQUIRED, AFTER THE FIRST 6 MONTHS OF THE GRANT, TO SUBMIT A WRITTEN SUMMARY TO BCAN DOCUMENTING THE PROGRESS MADE IN COMPLETING THE RESEARCH PROCESS. FORM 990, PART VI, SECTION A, LINE 4 ARTICLE VII BLADDER CANCER RESEARCH NETWORK SECTION 7.1 ESTABLISHMENT OF BLADDER CANCER RESEARCH NETWORK AND CORE MISSION. (A) THE BLADDER CANCER RESEARCH NETWORK ("BCRN") IS HEREBY ESTABLISHED AS A DIVISION OF THE CORPORATION BY THE BOARD OF DIRECTORS IN ACCORDANCE WITH THIS ARTICLE VII. (B) THE CORE MISSION OF BCRN IS TO MEET TO CONSIDER AND DISCUSS ISSUES OF SIGNIFICANCE WHICH REFLECT THE PURPOSE OF THE CORPORATION, INCLUDING (BUT NOT LIMITED TO) ISSUES CONCERNING IMPROVEMENT OF PATIENT CARE AND ELIMINATING DEATHS DUE TO BLADDER CANCER THROUGH COLLABORATIVE PATIENT-ORIENTED LABORATORY AND CLINICAL RESEARCH. (C) BCRN WILL WORK WITH THE BOARD OF DIRECTORS TO DEVELOP A FUNDRAISING PLAN TO OBTAIN THE NECESSARY FUNDS FOR INFRASTRUCTURE TO SUPPORT ITS CORE MISSION. THIS INCLUDES BUT IS NOT LIMITED TO ADMINISTRATIVE AND FUNDING SUPPORT FOR TISSUE BANKING, DATABASE SUPPORT AND DIRECT FUNDING OF RESEARCH. ANY SUCH FUNDRAISING PLANS SHALL BE SUBJECT TO THE APPROVAL OF THE BOARD OF DIRECTORS. SECTION 7.2 BCRN MANAGEMENT COMMITTEE. (A) THE BCRN WILL BE MANAGED BY THE BCRN MANAGEMENT COMMITTEE, WITHIN THE SCOPE OF AUTHORITY SET FORTH IN SECTION 7.5 OR AS MAY OTHERWISE BE GRANTED TO IT, FORM TIME TO TIME, BY THE BOARD OF DIRECTORS. (B) THE NUMBER OF PERSONS CONSTITUTING THE ENTIRE BCRN MANAGEMENT COMMITTEE SHALL BE THE NUMBER DETERMINED BY THE BOARD OF DIRECTORS, FROM TIME TO TIME. THE BOARD OF DIRECTORS SHALL CONSIDER THE RECOMMENDATIONS AND ADVICE OF THE BCRN COMMITTEE MEMBERS PRIOR TO MAKING A DETERMINATION UNDER THIS SECTION 7.2(B). (C) THE BOARD OF DIRECTORS SHALL APPOINT EACH PERSON (A "BCRN COMMITTEE MEMBER") WHO WILL BE A MEMBER OF THE BCRN MANAGEMENT COMMITTEE AND SHALL DETERMINE, FROM TIME TO TIME, THE TERM AND QUALIFICATIONS OF BCRN COMMITTEE MEMBERS. THE BOARD OF DIRECTORS SHALL CONSIDER THE RECOMMENDATIONS AND ADVICE OF THE BCRN COMMITTEE MEMBERS PRIOR TO MAKING A DETERMINATION AS TO THE TERM AND QUALIFICATIONS OF BCRN COMMITTEE MEMBERS UNDER THIS SECTION 7.2(C). (D) THE BCRN MANAGEMENT COMMITTEE SHALL BE DIVIDED INTO 2 CLASSES, WITH SAID CLASSES TO BE AS EQUAL IN NUMBER AS MAY BE POSSIBLE. AT THE FIRST ELECTION OR APPOINTMENT OF MEMBERS TO SUCH CLASSIFIED BCRN MANAGEMENT COMMITTEE, EACH CLASS 1 BCRN COMMITTEE MEMBER SHALL BE ELECTED TO SERVICE UNTIL THE SECOND ENSUING ANNUAL MEETING OF THE BCRN MANAGEMENT COMMITTEE AND EACH CLASS 2 BCRN COMMITTEE MEMBER SHALL BE ELECTED TO SERVE UNTIL THE THIRD ENSUING ANNUAL MEETING OF THE BCRN MANAGEMENT COMMITTEE. FOLLOWING THE EXPIRATION OF THEIR INITIAL TERMS, BCRN COMMITTEE MEMBERS IN EACH CLASS SHALL BE ELECTED FOR TERMS OF 3 YEARS TO SUCCEED THOSE WHOSE TERMS HAVE EXPIRED. NOTWITHSTANDING ANY OF THE FOREGOING PROVISIONS OF THIS ARTICLE VII, BCRN COMMITTEE MEMBERS SHALL SERVE UNTIL THEIR SUCCESSORS ARE ELECTED AND QUALIFIED OR UNTIL DEATH, RESIGNATION OR REMOVAL FROM OFFICE OR UNTIL THERE IS A DECREASE IN THE NUMBER OF BCRN COMMITTEE MEMBERS. (E) THE BCRN COMMITTEE MEMBERS SHALL BE INITIALLY CONSTITUTED OF 15 MEMBERS REPRESENTING A VARIETY OF SPECIALTIES: FOUR (4) UROLOGISTS; THREE (3) MEDICAL ONCOLOGISTS; TWO (2) BASIC SCIENTISTS; ONE (1) POPULATION SCIENTIST; ONE (1) PATHOLOGIST; ONE (1) RADIATION ONCOLOGIST; TWO (2) SURVIVORS; AND ONE (1) MEMBER OF BCAN'S BOARD OF DIRECTORS. IN ADDITION, BCAN'S SAB CHAIR, THE CHAIR OF THE THINK TANK PROGRAM COMMITTEE, AND A REPRESENTATIVE OF THE NCI'S BLADDER CANCER SPORE WILL SERVE IN EX OFFICIO CAPACITIES. (F) FOR AS LONG AS THE BCRN IS IN EXISTENCE, TWO (2) BCRN COMMITTEE MEMBERS (EXCLUDING THE BCRN COMMITTEE MEMBER WHO WAS A MEMBER OF THE BOARD OF DIRECTORS IMMEDIATELY PRIOR TO HER APPOINTMENT AS A BCRN COMMITTEE MEMBER) SHALL, BY VIRTUE OF THEIR APPOINTMENT AS A BCRN COMMITTEE MEMBER, BE DIRECTORS OF THE CORPORATION AND SHALL BE KNOWN AS THE "BCRN DIRECTORS". THE BCRN DIRECTORS WILL BE APPOINTED, AND MAY BE REMOVED AND REPLACED BY, A TWO-THIRDS MAJORITY VOTE OF THE BCRN MANAGEMENT COMMITTEE. SECTION 7.3 RESIGNATION AND REMOVAL. (A) A BCRN COMMITTEE MEMBER MAY RESIGN AT ANY TIME UPON WRITTEN NOTICE TO THE BCRN MANAGEMENT COMMITTEE AND THE BOARD OF DIRECTORS. SUCH RESIGNATION SHALL TAKE EFFECT AT THE LATER TIME SPECIFIED IN THE NOTICE OR THE DATE THE NOTICE IS DELIVERED TO THE BOARD OF DIRECTORS. (B) ANY ONE OR MORE OF THE BCRN COMMITTEE MEMBERS MAY BE REMOVED FOR CAUSE AT ANY TIME BY AFFIRMATIVE VOTE OF EIGHTY PER CENT (80%) OF THE ENTIRE BOARD OF DIRECTORS. SECTION 7.4 VACANCIES. THE BOARD OF DIRECTORS MAY AT ANY TIME APPOINT A PERSON TO BE A BCRN COMMITTEE MEMBER TO FILL A VACANCY. THE BOARD OF DIRECTORS SHALL CONSIDER THE RECOMMENDATIONS AND ADVICE OF THE BCRN MANAGEMENT COMMITTEE PRIOR TO MAKING AN APPOINTMENT UNDER THIS SECTION 7.4. SECTION 7.5 ACTIVITIES OF THE BCRN MANAGEMENT COMMITTEE. THE BCRN MANAGEMENT COMMITTEE IS HEREBY AUTHORIZED TO: (A) DEVELOP, COORDINATE AND MANAGE AN ANNUAL MEETING, TO BE KNOWN AS THE BLADDER CANCER THINK TANK, HOSTED BY THE CORPORATION, TO FURTHER THE PURPOSES OF THE CORPORATION AND BCRN; (B) DEVELOP A LIST OF BLADDER CANCER RESEARCH PRIORITIES FOR APPROVAL BY THE BOARD OF DIRECTORS; (C) RECEIVE, REVIEW AND MAKE RECOMMENDATIONS REGARDING RESEARCH PROPOSALS TO BE ENGAGE IN BY BCRN AND/OR TO BE SUPPORTED BY BCRN; AND (D) DO SUCH OTHER THINGS AS THE BOARD OF DIRECTORS DELEGATE TO IT, FROM TIME TO TIME. SECTION 7.6 MEETINGS OF THE BCRN MANAGEMENT COMMITTEE. (A) THE BCRN COMMITTEE MEMBERS SHALL MEET AT LEAST TWICE PER YEAR FOR CONDUCTING BUSINESS (AT LEAST ONE IN-PERSON MEETING), AND MAY ADJOURN OR OTHERWISE REGULATE THEIR MEETINGS IN ACCORDANCE WITH RULES AND GUIDELINES SET BY THE BOARD OF DIRECTORS FROM TIME TO TIME AS THEY THINK FIT. (B) THE BOARD OF DIRECTORS, OR A MAJORITY OF BCRN COMMITTEE MEMBERS, MAY CONVENE MEETINGS OF THE BCRN MANAGEMENT COMMITTEE IF IT DETERMINES THAT IT IS NECESSARY OR DESIRABLE TO DO SO. SECTION 7.7 VOTES AND QUESTIONS DECIDED BY MAJORITY FO THE BCRN MANAGEMENT COMMITTEE. A QUESTION ARISING AT A MEETING OF THE BCRN MANAGEMENT COMMITTEE SHALL BE DECIDED BY A MAJORITY OF VOTES OF THE MEMBERS PRESENT AND THAT DECISION IS FOR ALL PURPOSES A DECISION OF THE BCRN MANAGEMENT COMMITTEE. SECTION 7.8 RESPONSIBILITIES. THE BCRN MANAGEMENT COMMITTEE SHALL: (A) COMPLY WITH THE VALUES AND PURPOSES OF THE CORPORATION; (B) PROMPTLY ADOPT A CONFLICTS OF INTEREST POLICY, IN THE FORM APPROVED BY THE BOARD OF DIRECTORS; AND (C) COMPLY WITH ALL POLICIES AND PROCEDURES OF THE CORPORATION. SECTION 7.9 ACCESS TO RESOURCES. STAFF OF THE CORPORATION AND THE BOARD OF DIRECTORS WILL SUPPORT THE ACTIVITIES OF BCRN THROUGH THEIR TIME AND PROVISION OF THE CORPORATION'S RESOURCES TO THE EXTENT THE BOARD OF DIRECTORS THINKS NECESSARY OR DESIRABLE. SECTION 7.10 TASKFORCES. THE BCRN MANAGEMENT COMMITTEE MAY ESTABLISH TASKFORCES, EACH TASKFORCE TO CONSIST OF AT LEAST ONE (1) BCRN COMMITTEE MEMBER WHO IS A LAY PERSON, TO ASSIST BCRN OR THE CORPORATION IN PROJECTS OR WITH STRATEGY DEVELOPMENTS. SECTION 7.11 AMENDMENT. THIS ARTICLE VII MAY BE AMENDED OR REPEALED IN WHOLE OR IN PART BY THE AFFIRMATIVE VOTE OF TWO-THIRDS OR THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11 THE TREASURER REVIEWS THE ANNUAL FORM 990 AND THE ANNUAL AUDIT WITH THE AUDITOR, AND PRESENTS BOTH TO THE BOARD OF DIRECTORS FOR APPROVAL AS BCAN'S ANNUAL AUDITED FINANCIAL STATEMENTS. FORM 990, PART VI, SECTION B, LINE 12C ANNUALLY, EACH BOARD MEMBER, OFFICER, AND MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS SIGNS A STATEMENT WHICH AFFIRMS THEY HAVE READ AND ARE COMPLYING WITH BCAN'S CONFLICT OF INTEREST POLICIES. FORM 990, PART VI, SECTION B, LINE 15 TO DETERMINE APPROPRIATE COMPENSATION FOR BCANS EXECUTIVE DIRECTOR, THE OFFICERS ANNUALLY REVIEW THE MOST RECENTLY AVAILABLE NONPROFIT SALARY SURVEYS FOR THE DC METROPOLITAN AREA BEFORE DESIGNATING A SALARY RANGE BASED ON THE EXECUTIVE DIRECTORS SKILLS AND EXPERIENCE. THE PROPOSED COMPENSATION IS SUBJECT TO APPROVAL BY THE BOARD OF DIRECTORS. BCAN'S OFFICERS DO NOT DRAW ANY SALARY, NOR DO THEY GET REIMBURSED FOR TRAVEL TO BOARD MEETINGS. THE APPROPRIATE COMPENSATION FOR BCAN'S OTHER STAFF (CURRENTLY 1.5 FTE) IS REVIEWED AT LEAST ANNUALLY BY BCAN'S EXECUTIVE DIRECTOR. SHE REVIEWS THE MOST RECENTLY AVAILABLE NONPROFIT SALARY SURVEYS FOR THE DC METROPOLITAN AREA TO DESIGNATE A SALARY RANGE BASED ON STAFF'S SKILLS AND EXPERIENCE. THE PROPOSED COMPENSATION IS SUBJECT TO APPROVAL BY THE BOARD OF DIRECTORS EACH YEAR WHEN THEY APPROVE THE ANNUAL BUDGET. FORM 990, PART VI, SECTION C, LINE 19 BLADDER CANCER'S 990 AND DOCUMENTS ARE AVAILABLE TO THE PUBLIC BY REQUEST. THEY ALSO HAVE THE 990 AVAILABLE ON GUIDESTAR.ORG